Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 2/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14272268 | 0.94 | P2RX7 (0.40) | P2RX7MAPK14GRM5SCN9A | |
| SCHEMBL14272263 | 0.91 | P2RX7 (0.37) | P2RX7GRM5EPHX2 | |
| SCHEMBL14272270 | 0.90 | EPHX2 (0.39) | P2RX7GRM5EPHX2 | |
| SCHEMBL4990861 | 0.89 | P2RX7 (0.41) | P2RX7MAPK14EPHX2ALDH1A1 | |
| SCHEMBL4989551 | 0.87 | GRM5 (0.36) | P2RX7MAPK14GRM5EPHX2ALDH1A1 | |
| SCHEMBL14272266 | 0.85 | P2RX7 (0.39) | P2RX7ALDH1A1 | |
| SCHEMBL14300854 | 0.85 | P2RX7 (0.35) | P2RX7MAPK14EPHA2KDREPHB4 | |
| SCHEMBL14272262 | 0.85 | P2RX7 (0.44) | P2RX7ALDH1A1 | |
| SCHEMBL5142881 | 0.84 | P2RX7 (0.38) | P2RX7MAPK14 | |
| SCHEMBL5142363 | 0.83 | P2RX7 (0.52) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885MAPK14 655/4885EPHA2 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.